← Human Trials & Peer-Reviewed Studies
Levels of serum sclerostin, FGF-23, and intact parathyroid hormone in postmenopausal women treated with calcitriol
Plain-language guide to PMID 30532527 (2018): double-blind randomized controlled trial study of Parathyroid Hormone (PTH 1-84) in 141 women.
Key Facts
- PMID
- 30532527
- Journal
- Clinical interventions in aging
- Year
- 2018
- Study type
- Randomized Controlled Trial
- Authors
- Cheng Q et al. (8 authors)
- DOI
- 10.2147/CIA.S186199
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Parathyroid Hormone (PTH 1-84), published as a randomized controlled trial.
This study aimed to determine the effect of calcitriol on serum concentrations of fibroblast growth factor-23 (FGF-23), sclerostin, intact parathyroid hormone (PTH), and handgrip strength in postmenopausal women with low bone mass.
Who Took Part
The abstract describes 141 women taking part.
By PubMed's age tags, the people studied were middle-aged adults and older adults, women only.
A randomized, double-blind controlled trial was carried out among 141 postmenopausal women with low bone mass.
How the Study Was Run
The design is described as randomized, double-blind and placebo-controlled.
The women were allocated by chance, so the Parathyroid Hormone (PTH 1-84) group and the comparison group should start out alike.
Neither the women nor the staff measuring them knew who was on Parathyroid Hormone (PTH 1-84), so expectations could not easily colour the readings.
The comparison arm used a placebo, so changes seen with Parathyroid Hormone (PTH 1-84) could be set against what happens without it.
What Was Measured
PubMed files the paper under topics including Adaptor Proteins, Signal Transducing, Bone Morphogenetic Proteins, Calcitriol, Calcium, Calcium-Regulating Hormones and Agents, Drug Monitoring and Fibroblast Growth Factor-23.
The authors tagged it with the keywords FGF-23, fibroblast growth factor 23, handgrip, intact PTH and sclerostin.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Parathyroid Hormone (PTH 1-84) in 141 women.
The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2018 (Clinical interventions in aging), a journal based in New Zealand.
More context: the Parathyroid Hormone (PTH 1-84) compound page, all human trials.
Our Notes on the Compound
Parathyroid Hormone (PTH 1-84): The 84-amino-acid hormone that raises blood calcium; full-length PTH (Natpara) has been used in hypoparathyroidism. Teriparatide is its 1-34 fragment.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.